(602) 222-2221

Posts From October, 2018

Dr. Pravin U. Dugel: Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD

October 27, 2018 10:09 ET | Source:  Novartis International AG Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in central subfield thickness demonstrated at year one were reaffirmed at year two with brolucizumab 6 mg versus aflibercept Robust visual gains shown in… Read More »

Pravin U. Dugel, MD At EURETINA 2018: Brolucizumab For Neovascular Age-Related Macular Degeneration

   At this year’s EURETINA congress, we caught up with Dr Pravin Dugel to discuss neovascular age-related macular degeneration (nAMD). Dr Dugel suggests that while there have been recent advances in the treatment of nAMD, there is still a need to obtain better efficacy and find drugs that maintain visual acuity improvement over the… Read More »